TWI426073B - 抗黴菌組合物 - Google Patents

抗黴菌組合物 Download PDF

Info

Publication number
TWI426073B
TWI426073B TW096128916A TW96128916A TWI426073B TW I426073 B TWI426073 B TW I426073B TW 096128916 A TW096128916 A TW 096128916A TW 96128916 A TW96128916 A TW 96128916A TW I426073 B TWI426073 B TW I426073B
Authority
TW
Taiwan
Prior art keywords
chloro
methyl
propyl
hydroxy
difluorophenyl
Prior art date
Application number
TW096128916A
Other languages
English (en)
Chinese (zh)
Other versions
TW200823197A (en
Inventor
Canovas Paredes Antonio
Bartroli Orpi Javier
Molins Grau Elies
Roig Serra Anna
Meyer Kevin
Lorimer Keith
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39082545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI426073(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06380225A external-priority patent/EP1887004A1/en
Priority claimed from EP07380186A external-priority patent/EP2009009A1/en
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of TW200823197A publication Critical patent/TW200823197A/zh
Application granted granted Critical
Publication of TWI426073B publication Critical patent/TWI426073B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW096128916A 2006-08-07 2007-08-06 抗黴菌組合物 TWI426073B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83586306P 2006-08-07 2006-08-07
EP06380225A EP1887004A1 (en) 2006-08-07 2006-08-07 Crystalline forms of (1R,2R)-7-Chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one
US92940807P 2007-06-26 2007-06-26
EP07380186A EP2009009A1 (en) 2007-06-26 2007-06-26 Crystalline antifungal compounds

Publications (2)

Publication Number Publication Date
TW200823197A TW200823197A (en) 2008-06-01
TWI426073B true TWI426073B (zh) 2014-02-11

Family

ID=39082545

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096128916A TWI426073B (zh) 2006-08-07 2007-08-06 抗黴菌組合物

Country Status (17)

Country Link
US (2) US7879867B2 (en, 2012)
EP (2) EP2049504A4 (en, 2012)
JP (3) JP2010513222A (en, 2012)
KR (1) KR20090053903A (en, 2012)
CN (1) CN103232442B (en, 2012)
AR (1) AR062232A1 (en, 2012)
AU (1) AU2007284851B2 (en, 2012)
BR (1) BRPI0716026A2 (en, 2012)
CA (1) CA2658843A1 (en, 2012)
DK (1) DK2650291T3 (en, 2012)
ES (1) ES2652670T3 (en, 2012)
IL (2) IL196722A (en, 2012)
IN (1) IN2014MN01560A (en, 2012)
MX (1) MX2009001208A (en, 2012)
RU (1) RU2500679C2 (en, 2012)
TW (1) TWI426073B (en, 2012)
WO (1) WO2008021049A2 (en, 2012)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018853A2 (en) 2004-08-19 2006-02-23 Hetero Drugs Limited Novel polymorphs of efavirenz
PE20142329A1 (es) * 2006-04-05 2015-01-30 Opko Health Inc Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]decan-2-ona
ITMI20062449A1 (it) * 2006-12-19 2008-06-20 Dipharma Spa Forma cristallina di rabeprazolo sodico
WO2010138674A1 (en) * 2009-05-29 2010-12-02 Stiefel Laboratories, Inc. Azole antifungal compositions
CA2767785A1 (en) * 2009-07-10 2011-01-13 Evolva Ag Diyne compositions
BR112012003263A2 (pt) * 2009-08-14 2015-09-22 Opko Health Inc formulações intravenosas de antagonistas de neuroquinina-1
US9435692B2 (en) 2014-02-05 2016-09-06 Lam Research Corporation Calculating power input to an array of thermal control elements to achieve a two-dimensional temperature output
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
GB201410407D0 (en) * 2014-06-11 2014-07-23 Univ Dundee And Syngene Internat Ltd Plc And Consejo Superior De Investigaciones Cientificas And Med Treatment of chagas disease
EA025187B1 (ru) * 2015-04-17 2016-11-30 Тагир Аббасели оглы Сулейманов Производное дитиокарбамата 2-((4-(4-метилпиперазин-1-ил)фенил)амино)-2-оксоетил4-этилпиперазин-1-карбодитиоат, обладающее антифунгальной активностью
CN118695852A (zh) 2021-12-22 2024-09-24 帕劳制药有限公司 多颗粒阿巴康唑组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005130A1 (en) * 1995-08-02 1997-02-13 J. Uriach & Cia. S.A. New pyrimidone derivatives with antifungal activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293500A1 (en) 1987-06-01 1988-12-07 American Cyanamid Company 3-heteroalkyl-2,4.quinzaoline-diones
GB8819308D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
TW218017B (en, 2012) 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
TW297813B (en, 2012) * 1993-09-24 1997-02-11 Takeda Pharm Industry Co Ltd
CA2134417A1 (en) 1993-12-22 1995-06-23 Katsumi Itoh Optically active azole derivatives, their production and use
WO1998039305A1 (en) 1997-03-05 1998-09-11 Takeda Chemical Industries, Ltd. Crystalline form of a bis 1,2,4-triazole compound
ES2159488B1 (es) 2000-03-07 2002-04-16 Uriach & Cia Sa J Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005130A1 (en) * 1995-08-02 1997-02-13 J. Uriach & Cia. S.A. New pyrimidone derivatives with antifungal activity

Also Published As

Publication number Publication date
MX2009001208A (es) 2009-04-14
EP2650291B1 (en) 2017-10-04
JP2014012673A (ja) 2014-01-23
US7879867B2 (en) 2011-02-01
US20080076787A1 (en) 2008-03-27
JP2015193642A (ja) 2015-11-05
RU2009104959A (ru) 2010-08-20
AU2007284851B2 (en) 2013-05-09
TW200823197A (en) 2008-06-01
IN2014MN01560A (en, 2012) 2015-05-08
IL196722A (en) 2016-10-31
CA2658843A1 (en) 2008-02-21
CN103232442A (zh) 2013-08-07
AU2007284851A1 (en) 2008-02-21
WO2008021049A2 (en) 2008-02-21
US20110092702A1 (en) 2011-04-21
IL248216B (en) 2018-03-29
CN103232442B (zh) 2015-01-21
WO2008021049A9 (en) 2008-10-30
ES2652670T3 (es) 2018-02-05
KR20090053903A (ko) 2009-05-28
RU2500679C2 (ru) 2013-12-10
IL196722A0 (en) 2009-11-18
EP2049504A2 (en) 2009-04-22
AR062232A1 (es) 2008-10-22
EP2650291A1 (en) 2013-10-16
US8258296B2 (en) 2012-09-04
EP2049504A4 (en) 2010-09-22
JP2010513222A (ja) 2010-04-30
BRPI0716026A2 (pt) 2013-08-06
WO2008021049A3 (en) 2008-12-31
DK2650291T3 (en) 2017-10-23

Similar Documents

Publication Publication Date Title
TWI426073B (zh) 抗黴菌組合物
KR101639456B1 (ko) 포사코나졸의 결정질 형태
TW200815439A (en) Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
JP2022530441A (ja) 7h-ピロロ[2,3-d]ピリミジンjak-阻害剤
US20160046603A1 (en) Crystalline Forms of D-Glucitol, 1-Deoxy-1-(Methylamino)-, 1-(6-Amino-3,5-Difluoropyridine-2-Yl)-8-Chloro-6-Fluoro-1,4-Dihydro-7-(3-Hydroxyazetidin-1-Yl)-4-Oxo-3-Quinolinecarboxylate
JP7168447B2 (ja) ビラスチンの結晶形態及びそれらの調製方法
JP5680161B1 (ja) 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
US12129238B2 (en) Crystalline form of propoxazepam, the method of its making and use as medicinal agent
JP5795693B2 (ja) 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
EP2009009A1 (en) Crystalline antifungal compounds
CN101516858B (zh) 晶体抗真菌化合物
RU2772222C2 (ru) Кристаллические формы биластина и способы их получения
WO2022235726A1 (en) Solid forms of (r)-oxybutynin d-malate
HK40052085A (en) Pharmaceutical compound, the method of its making and use as medicinal agent
HK40052085B (en) Pharmaceutical compound, the method of its making and use as medicinal agent

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees